Response to “Reassessing the death risk related to probiotics in critically ill patients”
© The Author(s). 2017
Published: 27 February 2017
We would like to thank Dr. Maraolo for his valuable and careful analysis  of the data of our recently published systematic review and meta-analysis on probiotic and synbiotic therapy in the critically ill . As Dr. Maraolo has observed we have made an error in the calculation of the pooled risk ratio (RR) and 95% confidence interval (CI) for the effect of probiotics on hospital mortality. When we abstracted mortality data from the Besselink et al.  study we included correct data in both arms (24 of 152 and 9 of 144 patients in the probiotic and placebo groups, respectively). Nonetheless, we made a mistake creating the forest plot. Please, accept our sincere apologies.
Having said that, the conclusion of our meta-analysis remains unchanged. According to our findings probiotic therapy may be associated with a significant reduction in overall new infections, including new episodes of ventilator-associated pneumonia. However, no benefits in terms of reduction in mortality or another relevant clinical outcome for critically ill patients have been pointed out.
No funding was needed for this letter.
Availability of data and materials
WM and PW wrote and edited the letter. Both authors read and approved the final version of the manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethical approval and consent to participate
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Maraolo AE. Reassessing the death risk related to probiotics in critically ill patients. Crit Care. 2016;20:338.View ArticleGoogle Scholar
- Manzanares W, Lemieux M, Langlois PL, Wischmeyer PE. Probiotic and synbiotic therapy in critical illness: a systematic review and meta-analysis. Crit Care. 2016;20:262.View ArticlePubMed CentralGoogle Scholar
- Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Witteman BJ, Rosman C, Ploeg RJ, Brink MA, Schaapherder AF, Dejong CH, Wahab PJ, van Laarhoven CJ, Van der Harst E, van Eijck CH, Cuesta MA, Akkermans LM, Gooszen HG, Dutch Acute Pancreatitis Study Group. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind,placebo-controlled trial. Lancet. 2008;371:651–9.View ArticlePubMedGoogle Scholar
- Urben LM, Wiedmar J, Boettcher E, Cavallazzi R, Martindale RG, McClave SA. Bugs or drugs: are probiotics safe for use in the critically ill? Curr Gastroenterol Rep. 2014;16:388.View ArticlePubMedGoogle Scholar